NASDAQ:BOLD - Audentes Therapeutics Stock Price, Forecast & News

$59.97

0.00 (0.00 %)

(As of 01/20/2020 01:02 AM ET)

Add

Compare

Today's Range

$59.97

Now: $59.97▼

$59.97

50-Day Range

$28.60

MA: $57.19▼

$60.00

52-Week Range

$22.00

Now: $59.97▼

$60.00

VolumeN/A

Average Volume1.50 million shs

Market Capitalization$2.77 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.18

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:BOLD

Previous Symbol

CUSIPN/A

CIK1628738

Webhttp://www.audentestx.com/

Phone415-818-1001

Debt

Debt-to-Equity RatioN/A

Current Ratio12.80

Quick Ratio12.79

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value($7.48) per share

Price / Book-8.02

Profitability

EPS (Most Recent Fiscal Year)($3.40)

Net Income$-128,820,000.00

Net MarginsN/A

Return on EquityN/A

Return on Assets-38.00%

Miscellaneous

Employees207

Outstanding Shares46,272,000

Market Cap$2.77 billion

Next Earnings Date2/26/2020 (Estimated)

OptionableOptionable

Receive BOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter.

(Ad)

Each week, an exclusive group of investors receives access to a simple list of 3 stocks to put on their radar for the week ahead.

You can sign up today to receive access to next week's watchlist -- generated by a proprietary methodology -- at no cost or obligation.

Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics Inc (NASDAQ:BOLD) posted its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($1.00) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.07. During the same quarter in the previous year, the business earned ($0.97) EPS. View Audentes Therapeutics' Earnings History.

When is Audentes Therapeutics' next earnings date?

Audentes Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Audentes Therapeutics.

What price target have analysts set for BOLD?

17 brokers have issued twelve-month target prices for Audentes Therapeutics' stock. Their forecasts range from $10.00 to $60.00. On average, they anticipate Audentes Therapeutics' stock price to reach $50.54 in the next year. This suggests that the stock has a possible downside of 15.7%. View Analyst Price Targets for Audentes Therapeutics.

What is the consensus analysts' recommendation for Audentes Therapeutics?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 14 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Audentes Therapeutics.

What are Wall Street analysts saying about Audentes Therapeutics stock?

Here are some recent quotes from research analysts about Audentes Therapeutics stock:

1. According to Zacks Investment Research, "Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company's product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. " (1/13/2020)
2. HC Wainwright analysts commented, "Our $44 (raised from $33) price target on shares of Audentes is based on a 12-year DCF-based, sum-of-the-parts analysis, which includes AT132 being developed for XLMTM and AT845, that is being advanced as a one-and-done approach for Pompe disease. Note, our prior $33 target, did not reflect AT-845. Our DCF is driven by a: beta of 1.25, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.0%, and tax rate of 15% beginning in FY 2028." (3/18/2019)

Has Audentes Therapeutics been receiving favorable news coverage?

Media headlines about BOLD stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Audentes Therapeutics earned a news impact score of 3.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Audentes Therapeutics.

Who are some of Audentes Therapeutics' key competitors?

Some companies that are related to Audentes Therapeutics include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), bluebird bio (BLUE), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO) and Iovance Biotherapeutics (IOVA).

What other stocks do shareholders of Audentes Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Energy Transfer LP Unit (ET), Exelixis (EXEL), Global Blood Therapeutics (GBT), Gilead Sciences (GILD), Intel (INTC), bluebird bio (BLUE), Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), Ionis Pharmaceuticals (IONS) and Myriad Genetics (MYGN).

Who are Audentes Therapeutics' key executives?

Audentes Therapeutics' management team includes the folowing people:

Mr. Matthew R. Patterson, Co-Founder, Chairman & CEO (Age 47)
Ms. Natalie C. Holles, Pres & COO (Age 46)
Mr. Thomas P. Soloway, Exec. VP & CFO (Age 52)
Dr. John T. Gray, Sr. VP & Chief Scientific Officer (Age 56)
Mr. Andrew H. Chang, Director of Investor Relations

When did Audentes Therapeutics IPO?

(BOLD) raised $75 million in an IPO on Wednesday, July 20th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Audentes Therapeutics' major shareholders?

Audentes Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Syquant Capital Sas (1.66%), FNY Investment Advisers LLC (0.60%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Audentes Therapeutics stock include David Nagler, John T Gray, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc and Suyash Prasad. View Institutional Ownership Trends for Audentes Therapeutics.

Which major investors are buying Audentes Therapeutics stock?

BOLD stock was bought by a variety of institutional investors in the last quarter, including Syquant Capital Sas, FNY Investment Advisers LLC and Nisa Investment Advisors LLC. View Insider Buying and Selling for Audentes Therapeutics.

How do I buy shares of Audentes Therapeutics?

Shares of BOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Audentes Therapeutics' stock price today?

One share of BOLD stock can currently be purchased for approximately $59.97.

How big of a company is Audentes Therapeutics?

Audentes Therapeutics has a market capitalization of $2.77 billion. The biotechnology company earns $-128,820,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 207 workers across the globe.View Additional Information About Audentes Therapeutics.

What is Audentes Therapeutics' official website?

The official website for Audentes Therapeutics is http://www.audentestx.com/.

How can I contact Audentes Therapeutics?

Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected]

MarketBeat Community Rating for Audentes Therapeutics (NASDAQ BOLD)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		438 (Vote Outperform)
Underperform Votes:		396 (Vote Underperform)
Total Votes:		834

MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe BOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/20/2020 by MarketBeat.com Staff

Featured Article: Initial Coin Offerings entail a high degree of risk

Your Ultimate Investing Toolkit

Just $1.00 for your first month.